Table 3.
Univariate and multivariate Cox proportional hazards regression (final model) for death without appropriate shock
| Univariate |
Multivariate |
|||
|---|---|---|---|---|
| HR [95% CI] | P-value | HR (95% CI) | P-value | |
| Age (years) | 1.063 [1.048–1.078] | <0.001 | 1.04 [1.03–1.06] | <0.001 |
| Sex category (male) | 1.204 [0.850–1.705] | 0.295 | 1.09 [0.77–1.55] | 0.708 |
| Body mass index (kg/m2) | 0.972 [0.942–1.003] | 0.076 | ||
| NYHA functional class | 1.711 [1.456–2.011] | <0.001 | ||
| Primary prophylactic indication | 1.658 [1.269–2.167] | <0.001 | ||
| CRT-D | 1.575 [1.216–2.039] | <0.001 | ||
| Ischaemic cardiomyopathy | 1.446 [1.080–1.936] | 0.013 | ||
| LVEF (%) | 0.974 [0.962–0.986] | <0.001 | ||
| Heart rate (b.p.m.) | 1.002 [0.998–1.006] | 0.298 | ||
| QRS duration (ms) | 1.007 [1.003–1.011] | <0.001 | ||
| QT interval (ms) | 1.001 [0.998–1.004] | 0.383 | ||
| eGFR (mL/min/1.73 m2) | 0.977 [0.971–0.983] | <0.001 | 0.99 [0.98–1.00] | 0.008 |
| Medication | ||||
| ACE inhibitors/ARB | 1.035 [0.696–1.541] | 0.864 | ||
| β-Blocker | 0.864 [0.577–1.293] | 0.477 | ||
| Digitalis | 1.558 [1.191–2.038] | 0.001 | 1.47 [1.11–1.94] | 0.021 |
| Diuretics | 2.925 [1.967–4.351] | <0.001 | 1.79 [1.19–2.69] | 0.016 |
| MRA | 1.014 [0.776–1.324] | 0.920 | ||
| Aspirin | 1.090 [0.832–1.428] | 0.530 | ||
| Coumadin | 1.268 [0.955–1.683] | 0.100 | ||
| Amiodarone | 1.071 [0.784–1.463] | 0.665 | ||
| Hypertension | 1.229 [0.868–1.741] | 0.244 | ||
| Diabetes | 1.509 [1.150–1.980] | 0.003 | ||
| History of atrial fibrillation | 1.594 [1.233–2.060] | <0.001 | ||
| Peripheral arterial disease | 3.474 [2.521–4.788] | <0.001 | 2.46 [1.76–3.44] | <0.001 |
| COPD | 2.003 [1.476–2.719] | <0.001 | 1.48 [1.08–2.02] | 0.040 |
AAD, antiarrhythmic drug; AF, atrial fibrillation; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; aspirin, acetylsalicylic acid; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CRT-D, cardiac resynchronization therapy with defibrillator; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LV, left ventricular; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.